Home Newsfeeds Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $13

Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $13

Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ:LUNG) with a Overweight and lowers the price target from $25 to $13.

November 4, 2022

1 minute read

Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ:LUNG) with a Overweight and lowers the price target from $25 to $13.

Morgan Stanley Maintains Equal-Weight on US Foods Hldg, Lowers Price Target to $39

July 18, 10:10 AM

Morgan Stanley analyst John Glass maintains US Foods Hldg (NYSE:USFD) with a Equal-Weight and lowers the price target from $42 to $39.

July 12, 2:51 PM

The Coca-Cola Company (NYSE: KO) and eight global bottling partners have closed a new $137.7 million venture capital fund

July 27, 12:35 PM

Garrett Motion Inc (NASDAQ: GTX) reported a Q2 FY23 sales of $1.01 billion, up 18% on a GAAP basis, up 19% at constant currency, beating the

November 22, 12:19 PM

Shares of Virgin Galactic Holdings Inc (NYSE: SPCE) tanked in premarket trading on Wednesday, along with some other top stocks.